Pandemic Spotlights Tensions Between Profit And Philanthropy

Competition Remains Amid Industry’s Remarkable Efforts to Fight COVID-19

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Global management
• Source: Shutterstock

The quest for vaccines and therapeutics against COVID-19 has driven together institutions, companies, countries and scientific communities. Rivals have become partners and R&D timelines have shrunk: just 10 months following the publication of the viral gene-sequence for SARS-CoV-2, 11 vaccine candidates had started Phase III trials. By mid November 2020, highly promising efficacy results had emerged from two of those vaccines, including a vaccine candidate from partners Pfizer Inc. and BioNTech SE.

Data-sharing has expanded, between and among companies and academic institutions, and efforts have grown to integrate disparate data sources, including...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo